- GlobeNewswire•4 hours agoChemoCentryx to Hold Third Quarter 2016 Financial Results Conference Call on Monday, November 7, 2016
MOUNTAIN VIEW, Calif., Oct. 28, 2016-- ChemoCentryx, Inc.,, today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016. ChemoCentryx ...
- GlobeNewswire•yesterdayChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy
MOUNTAIN VIEW, Calif., Oct. 27, 2016-- ChemoCentryx, Inc.,, today announced that its orally administered complement 5 a receptor inhibitor CCX168 has shown a beneficial effect on disease in a patient with ...
- GlobeNewswire•8 days ago
MOUNTAIN VIEW, Calif., Oct. 20, 2016-- ChemoCentryx, Inc.,, today announced that effective October 17, 2016, Henry A. McKinnell, Jr, Ph.D., retired chairman and chief executive officer of Pfizer Inc., ...
ChemoCentryx, Inc. (CCXI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||6.00 x 900|
|Ask||6.03 x 100|
|Day's Range||6.00 - 6.34|
|52wk Range||1.92 - 8.30|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.54|
|Avg Vol (3m)||186,289|
|Dividend & Yield||N/A (N/A)|